Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

88.1 EUR
+0.2 (+0.23%)
Last: 12/23/2025, 7:00:00 PM
Fundamental Rating

5

Taking everything into account, ADN1 scores 5 out of 10 in our fundamental rating. ADN1 was compared to 76 industry peers in the IT Services industry. ADN1 has an average financial health and profitability rating. ADN1 is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

ADN1 had positive earnings in the past year.
In the past year ADN1 had a positive cash flow from operations.
In the past 5 years ADN1 has always been profitable.
ADN1 had a positive operating cash flow in each of the past 5 years.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.45%, ADN1 is in line with its industry, outperforming 40.79% of the companies in the same industry.
The Return On Equity of ADN1 (10.90%) is comparable to the rest of the industry.
The Return On Invested Capital of ADN1 (5.23%) is worse than 63.16% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ADN1 is significantly below the industry average of 26.78%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

With a Profit Margin value of 0.99%, ADN1 is not doing good in the industry: 61.84% of the companies in the same industry are doing better.
ADN1's Profit Margin has declined in the last couple of years.
The Operating Margin of ADN1 (2.96%) is worse than 67.11% of its industry peers.
In the last couple of years the Operating Margin of ADN1 has declined.
ADN1 has a Gross Margin of 85.30%. This is in the better half of the industry: ADN1 outperforms 76.32% of its industry peers.
In the last couple of years the Gross Margin of ADN1 has remained more or less at the same level.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADN1 is destroying value.
ADN1 has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ADN1 has been increased compared to 5 years ago.
The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ADN1 has an Altman-Z score of 3.62. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.62, ADN1 is doing good in the industry, outperforming 76.32% of the companies in the same industry.
ADN1 has a debt to FCF ratio of 7.88. This is a slightly negative value and a sign of low solvency as ADN1 would need 7.88 years to pay back of all of its debts.
ADN1 has a worse Debt to FCF ratio (7.88) than 64.47% of its industry peers.
A Debt/Equity ratio of 1.60 is on the high side and indicates that ADN1 has dependencies on debt financing.
ADN1 has a Debt to Equity ratio of 1.60. This is in the lower half of the industry: ADN1 underperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.62
ROIC/WACC0.94
WACC5.55%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

ADN1 has a Current Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
ADN1 has a Current ratio of 1.30. This is comparable to the rest of the industry: ADN1 outperforms 56.58% of its industry peers.
A Quick Ratio of 1.30 indicates that ADN1 should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.30, ADN1 is doing good in the industry, outperforming 64.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 200.98% over the past year.
The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
ADN1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
Measured over the past years, ADN1 shows a very strong growth in Revenue. The Revenue has been growing by 23.60% on average per year.
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

Based on estimates for the next years, ADN1 will show a very strong growth in Earnings Per Share. The EPS will grow by 39.75% on average per year.
The Revenue is expected to grow by 10.61% on average over the next years. This is quite good.
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 27.62 indicates a quite expensive valuation of ADN1.
ADN1's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of ADN1 to the average of the S&P500 Index (26.59), we can say ADN1 is valued inline with the index average.
ADN1 is valuated correctly with a Price/Forward Earnings ratio of 15.58.
The rest of the industry has a similar Price/Forward Earnings ratio as ADN1.
ADN1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.62
Fwd PE 15.58
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

69.74% of the companies in the same industry are more expensive than ADN1, based on the Enterprise Value to EBITDA ratio.
ADN1's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ADN1 is cheaper than 61.84% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.31
EV/EBITDA 6.58
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

ADN1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADN1's earnings are expected to grow with 63.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y76.08%
EPS Next 3Y63.28%

4

5. Dividend

5.1 Amount

ADN1 has a yearly dividend return of 0.87%, which is pretty low.
Compared to an average industry Dividend Yield of 2.27, ADN1 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.88, ADN1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.87%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

31.75% of the earnings are spent on dividend by ADN1. This is a low number and sustainable payout ratio.
The dividend of ADN1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP31.75%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (12/23/2025, 7:00:00 PM)

88.1

+0.2 (+0.23%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-31 2026-03-31/amc
Inst Owners20.45%
Inst Owner ChangeN/A
Ins Owners50.28%
Ins Owner ChangeN/A
Market Cap575.29M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts81.54
Price Target126.63 (43.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.87%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.91%
PT rev (3m)-0.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.47%
EPS NY rev (3m)-12.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE 27.62
Fwd PE 15.58
P/S 0.27
P/FCF 12.31
P/OCF 7.41
P/B 3.01
P/tB 11.36
EV/EBITDA 6.58
EPS(TTM)3.19
EY3.62%
EPS(NY)5.65
Fwd EY6.42%
FCF(TTM)7.16
FCFY8.13%
OCF(TTM)11.9
OCFY13.5%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.33
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.62
F-Score7
WACC5.55%
ROIC/WACC0.94
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.75%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.61%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year302.45%
EBIT Next 3Y80.25%
EBIT Next 5Y44.55%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


What is the valuation status of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the valuation of ADESSO SE based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 27.62 and the Price/Book (PB) ratio is 3.01.


Is the dividend of ADESSO SE sustainable?

The dividend rating of ADESSO SE (ADN1.DE) is 4 / 10 and the dividend payout ratio is 31.75%.